Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

January 3, 2024

https://www.globenewswire.com/news-release/2024/01/03/2803114/31990/en/Agios-Announces-Phase-3-ENERGIZE-Study-of-Mitapivat-Met-Primary-Endpoint-and-Both-Key-Secondary-Endpoints-in-Adults-with-Non-Transfusion-Dependent-Alpha-or-Beta-Thalassemia.html

–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo –

– Statistical Significance Also Achieved for Key Secondary Endpoints of Change From Baseline in Both FACIT-Fatigue Score and Hemoglobin Concentration –

Read more at globenewswire.com

Related news for (AGIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.